ARVINAS, INC. (ARVN) — Inside-Filings

Sentiment-Signal

19,0

Stark Bearisch

Composite Score (0–100)

Insider (25%)

36.9

1 Insider, 268K $ Volumen

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Unternehmen & Branche

Name	ARVINAS, INC.
Ticker	ARVN
CIK	0001655759
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	651,1 Mio. USD
Beta	1,98
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	262,600,000	-80,800,000	-1.14	717,900,000	433,900,000
2025-09-30	10-Q	41,900,000	-35,100,000	-0.48	844,300,000	564,400,000
2025-06-30	10-Q	22,400,000	-61,200,000	-0.84	909,300,000	609,300,000
2025-03-31	10-Q	188,800,000	82,900,000	1.14	1,001,100,000	660,100,000
2024-12-31	10-K	263,400,000	-198,900,000	-2.77	1,091,400,000	561,700,000
2024-09-30	10-Q	102,400,000	-49,200,000	-0.68	1,167,100,000	586,000,000
2024-06-30	10-Q	76,500,000	-35,200,000	-0.49	1,279,600,000	600,200,000
2024-03-31	10-Q	25,300,000	-69,400,000	-0.97	1,212,600,000	609,700,000
2023-12-31	10-K	78,500,000	-367,300,000	-6.62	1,304,600,000	660,000,000
2023-09-30	10-Q	34,600,000	-64,000,000	-1.18	1,058,300,000	457,200,000
2023-06-30	10-Q	54,500,000	-66,600,000	-1.25	1,083,500,000	463,600,000
2023-03-31	10-Q	32,500,000	-81,900,000	-1.54	1,175,800,000	511,000,000
2022-12-31	10-K	131,400,000	-282,500,000	-5.31	1,268,800,000	564,900,000
2022-09-30	10-Q	33,200,000	-66,200,000	-1.24	1,334,800,000	621,500,000
2022-06-30	10-Q	33,800,000	-70,000,000	-1.32	1,407,000,000	670,600,000
2022-03-31	10-Q	26,500,000	-63,400,000	-1.20	1,488,300,000	723,300,000
2021-12-31	10-K	53,600,000	-191,000,000	-3.82	1,581,600,000	781,700,000
2021-09-30	10-Q	9,300,000	-46,800,000	-0.94	1,604,865,210	817,700,000
2021-06-30	10-Q	5,500,000	-50,300,000	-1.03	644,026,885	582,900,000
2021-03-31	10-Q	5,500,000	-41,000,000	-0.84	681,772,443	615,200,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-03-06	Morrison Briggs	Director	Open Market Purchase	20,000	13.40	268,070.00	+197,7%
2026-02-27	Houston John G	Director	Open Market Sale	-4,688	13.24	-62,069.12	-45,8%
2026-02-27	Houston John G	Director	Open Market Sale	-11,787	13.14	-154,881.18	-114,2%
2026-02-27	Houston John G	Director	Open Market Sale	-18,822	13.24	-249,203.28	-183,7%
2026-02-13	Saik Andrew	Officer, Chief Financial Officer	Open Market Sale	-5,134	11.89	-61,043.26	-45,0%
2025-09-22	Morrison Briggs	Director	Open Market Purchase	30,000	7.57	227,010.00	+167,4%
2025-06-24	Saik Andrew	Officer, Chief Financial Officer	Open Market Sale	-5,700	7.61	-43,377.00	-32,0%
2025-06-17	Cacace Angela M	Officer, Chief Scientific Officer	Open Market Sale	-2,583	7.49	-19,346.67	-14,3%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.